Cargando…

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma

The fibroblast growth factor (FGF) signaling cascade is one of the key signaling pathways in hepatocellular carcinoma (HCC). FGF has been shown to augment vascular endothelial growth factor (VEGF)-mediated HCC development and angiogenesis, as well as to potentially lead to resistance to VEGF/VEGF re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Thi Bich Uyen, Vu, Thanh Chung, Ho, Rebecca Zhi Wen, Prawira, Aldo, Wang, Lingzhi, Goh, Boon Cher, Huynh, Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764786/ https://www.ncbi.nlm.nih.gov/pubmed/33321903 http://dx.doi.org/10.3390/ijms21249405

Ejemplares similares

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)

FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma
por: Huynh, Hung, et al.
Publicado: (2020)

Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor
por: Prawira, Aldo, et al.
Publicado: (2021)

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
por: Yeoh, Kheng Wei, et al.
Publicado: (2020)

Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
por: Huynh, Hung, et al.
Publicado: (2019)

Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

Correction to: Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
por: Yu, James, et al.
Publicado: (2021)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

SUN-098 Low-Dose Infigratinib Treatment Does Not Lead to Changes in Phosphorous Preclinically in Mice
por: Reyes, Maribel, et al.
Publicado: (2020)

PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies
por: Muslimova, Elena, et al.
Publicado: (2022)

Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
por: White, Kathryn, et al.
Publicado: (2023)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Pan-CDK inhibition augments cisplatin lethality in nasopharyngeal carcinoma cell lines and xenograft models
por: Syn, Nicholas L., et al.
Publicado: (2018)

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia
por: Hartley, Iris R., et al.
Publicado: (2022)

Different treatment efficacies and side effects of cytotoxic chemotherapy
por: Li, Low-Jia, et al.
Publicado: (2020)

THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib
por: Savarirayan, Ravi, et al.
Publicado: (2023)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
por: Kong, Li Ren, et al.
Publicado: (2020)

Biomarkers for antitumor activity of bevacizumab in gastric cancer models
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2012)

THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials
por: Savarirayan, Ravi, et al.
Publicado: (2023)

Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma
por: Sedghipour, Mohammad-Reza, et al.
Publicado: (2011)

Effective Inhibition of Xenografts of Hepatocellular Carcinoma (HepG2) by Rapamycin and Bevacizumab in an Intrahepatic Model
por: Ong, Lai-Chun, et al.
Publicado: (2009)

Adopting the Swenson-like technique for patients with Hirschsprung disease in Vietnam
por: Nguyen, Bich-Uyen, et al.
Publicado: (2023)

Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice
por: Liu, Zhili, et al.
Publicado: (2019)

Detection of sFas, sCD137, and IL-27 Cytokines as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis
por: Do, Xuan-Hai, et al.
Publicado: (2023)

Integrating Health Behavior Theories to Predict Intention to Get a COVID-19 Vaccine
por: An, Pham Le, et al.
Publicado: (2021)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

Selective Stability Indicating Liquid Chromatographic Method Based on Quality by Design Framework and In Silico Toxicity Assessment for Infigratinib and Its Degradation Products
por: Ali, Awadh M., et al.
Publicado: (2023)

Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma
por: Kong, Li R., et al.
Publicado: (2017)

Induction of Antitumor Immunity by Exosomes Isolated from Cryopreserved Cord Blood Monocyte-Derived Dendritic Cells
por: Than, Uyen Thi Trang, et al.
Publicado: (2020)

Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy
por: Zarei, Reza, et al.
Publicado: (2016)

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
por: Lee, Matilda, et al.
Publicado: (2018)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

Identification and characterization of in silico, in vivo, in vitro, and reactive metabolites of infigratinib using LC-ITMS: bioactivation pathway elucidation and in silico toxicity studies of its metabolites
por: Al-Shakliah, Nasser S., et al.
Publicado: (2020)

PD-L1 and TILs expression and their association with clinicopathological characteristics in Vietnamese women with primary invasive breast cancer
por: Huynh, Chau Giang, et al.
Publicado: (2023)

Clinicopathological Risk Factors of Unfavorable Outcomes in Vietnamese Women with Primary Invasive Breast Cancer: A Retrospective Cohort Study
por: Huynh, Chau Giang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dcr5fthvlmadjq0p7p0hcpmqrc